IRIS
CARLOMAGNO, Chiara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 6.030
NA - Nord America 5.071
EU - Europa 3.969
SA - Sud America 664
Continente sconosciuto - Info sul continente non disponibili 175
AF - Africa 148
OC - Oceania 5
Totale 16.062
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.840
SG - Singapore 2.580
RU - Federazione Russa 1.818
VN - Vietnam 1.182
CN - Cina 1.100
IT - Italia 668
HK - Hong Kong 562
BR - Brasile 506
NL - Olanda 265
DE - Germania 251
FR - Francia 191
FI - Finlandia 186
IE - Irlanda 157
CA - Canada 134
UA - Ucraina 128
BD - Bangladesh 107
GB - Regno Unito 103
IN - India 98
JP - Giappone 91
SE - Svezia 72
AR - Argentina 57
MX - Messico 53
ZA - Sudafrica 42
CI - Costa d'Avorio 40
PH - Filippine 36
KR - Corea 32
IQ - Iraq 31
ID - Indonesia 29
CO - Colombia 26
EC - Ecuador 24
PL - Polonia 24
TR - Turchia 22
AT - Austria 20
ES - Italia 20
TH - Thailandia 19
PK - Pakistan 17
CZ - Repubblica Ceca 15
TW - Taiwan 14
MY - Malesia 13
VE - Venezuela 13
SA - Arabia Saudita 12
BE - Belgio 11
MA - Marocco 11
CL - Cile 10
JO - Giordania 10
TN - Tunisia 10
NP - Nepal 9
PT - Portogallo 9
IR - Iran 8
LT - Lituania 8
PE - Perù 8
UY - Uruguay 8
BG - Bulgaria 7
EG - Egitto 7
KE - Kenya 7
PY - Paraguay 7
AZ - Azerbaigian 6
DO - Repubblica Dominicana 6
ET - Etiopia 6
PS - Palestinian Territory 6
UZ - Uzbekistan 6
AE - Emirati Arabi Uniti 5
IL - Israele 5
PA - Panama 5
CR - Costa Rica 4
GT - Guatemala 4
LB - Libano 4
AL - Albania 3
BO - Bolivia 3
DZ - Algeria 3
EU - Europa 3
HN - Honduras 3
JM - Giamaica 3
MN - Mongolia 3
NI - Nicaragua 3
OM - Oman 3
QA - Qatar 3
SY - Repubblica araba siriana 3
TT - Trinidad e Tobago 3
XK - ???statistics.table.value.countryCode.XK??? 3
AO - Angola 2
AU - Australia 2
BB - Barbados 2
BF - Burkina Faso 2
CG - Congo 2
CV - Capo Verde 2
EE - Estonia 2
GA - Gabon 2
GE - Georgia 2
GR - Grecia 2
HT - Haiti 2
KN - Saint Kitts e Nevis 2
KW - Kuwait 2
KZ - Kazakistan 2
LK - Sri Lanka 2
MK - Macedonia 2
NZ - Nuova Zelanda 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
Totale 15.864
Salva come PNG Salva come JPEG
Città #
Singapore 1.235
San Jose 873
Hong Kong 544
Ashburn 479
Moscow 441
Beijing 366
Ho Chi Minh City 330
Chandler 325
Hanoi 279
Amsterdam 253
Santa Clara 216
Los Angeles 171
Millbury 171
Naples 137
The Dalles 126
Princeton 125
Lauterbourg 120
Munich 116
Nanjing 99
Napoli 92
Tokyo 78
Jacksonville 76
New York 74
Boston 66
Buffalo 60
Wilmington 60
Hefei 59
Haiphong 54
Dallas 52
São Paulo 52
Da Nang 50
Redondo Beach 47
Council Bluffs 43
Nanchang 43
Ottawa 42
Turku 42
Des Moines 41
Chicago 31
Jiaxing 31
Brooklyn 29
Houston 29
Mexico City 28
Tianjin 28
Frankfurt am Main 27
Montreal 25
Atlanta 24
Milan 24
Hải Dương 23
Washington 23
Denver 22
Rome 21
Orem 20
Helsinki 19
Nuremberg 19
Seattle 19
Toronto 19
Warsaw 19
Shenyang 18
Chennai 17
Ninh Bình 17
Biên Hòa 16
London 16
Lawrence 15
Shanghai 15
Stockholm 15
Woodbridge 15
Manchester 14
Poplar 14
Can Tho 13
Hebei 13
Johannesburg 13
San Francisco 13
Ann Arbor 12
Norwalk 12
Olomouc 12
Phoenix 12
Changsha 11
Charlotte 11
Falkenstein 11
Indiana 11
Seoul 11
Falls Church 10
Kochi 10
Kunming 10
Mumbai 10
Thái Nguyên 10
Tân Tiến 10
Baghdad 9
Belo Horizonte 9
Curitiba 9
Dublin 9
Guayaquil 9
Jeddah 9
Kuala Lumpur 9
Lentini 9
Pune 9
Rio de Janeiro 9
Dong Ket 8
Guangzhou 8
Istanbul 8
Totale 8.418
Salva come PNG Salva come JPEG
Nome #
A case report of limbic encephalitis in a metastatic colon cancer patient during first-line bevacizumab-combined chemotherapy 239
Manuale di Oncologia Clinica 234
STATO DELL'ARTE SULLA CHEMIOTERAPIA NEL CANCRO DEL COLON 191
Prognostic role of sarcopenia in metastatic colorectal cancer patients during first-line chemotherapy: A retrospective study 185
A specific miRNA signature correlates with complete pathological response to neoadjuvant chemo-radiotherapy in locally advanced rectal cancer 178
FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience 177
EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients. 166
The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer. 165
Evaluation of exercise capacity by means of cardiopulmonary exercise testing (CPET) in older adult cancer patients undergoing antineoplastic treatments 164
Discordance in RAS mutations between primary colon tumor and metastases: a real event or a matter of methodology? 162
Fast Detection of a BRCA2 Large Genomic Duplication by Next Generation Sequencing as a Single Procedure: A Case Report. 162
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 161
Addition of erlotinib to fluoropyrimidine-oxaliplatin-basedchemotherapy with or without bevacizumab: Two sequential phase I trials 158
Concomitant Interferon-alfa and chemotherapy in hepatitis C and colorectal cancer: a case report 157
Adjuvant treatment for locally advanced rectal cancer patients after pre-operative chemoradiotherapy: when, and for whom? 157
Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study. 154
Prevention of cardiovascular complications in elderly cancer patients 152
Primary hepatic lymphoma in a patient with previous rectal adenocarcinoma: a case report and discussion ofetiopathogenesis and diagnostic tools 151
Risk factors for cancer-related venous thromboembolism in ambulatory patients. 150
Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. 148
UbcH10 expression can predict prognosis and sensitivity to the antineoplastic treatment for colorectal cancer patients 148
Role of sphingosine kinase 1 (SphK1) on cetuximab resistance in colorectal cancer models 147
Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study 146
A phase I study of paclitaxel and epirubicin, without and with filgrastim, for the treatment of platinum-resistant advanced ovarian cancer. 144
Management of patients with BRCA1/2-associated breast cancer 142
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial 142
Double complete response in MCRC patient 141
Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study. 136
Adjuvant FOLFOX-4 in patients with radically resected gastric cancer: tolerability, and prognostic factors. 136
CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study). 135
Core curriculum. Oncologia clinica 132
Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study. 131
Neoadjuvant treatment with capecitabine and oxaliplatin in combination with radiotherapy for rectal cancer patients: a phase II study 130
SANGER SEQUENCING IN ROUTINE KRAS TESTING: AREVIEW OF 1720 CASES FROM A PATHOLOGIST’SPERSPECTIVE 129
MULTIDISCIPLINARY APPROACH TO PATIENTS WITH MALIGNANT MELANOMA 129
Cytological diagnosis of thyroid nodules in Hashimoto thyroiditis in elderly patients 129
MULTIPLE PRIMARY MALIGNANT NEOPLASM AND FAMILIAR ANAMNESIS 128
High-rsolution melting analysis (HRMA) for KRAS mutatiinal study in patients with metastatic colorectal cancer (mCRC pts) 128
Prognostic role of postoperative persistence of ctDNA molecular signature after liver resection for colorectal liver metastases: Preliminary results from a prospective study 127
Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review 127
The Epithelial-Stromal Interaction as a Potential Target for Breast Cancer Treatment 126
Analysis of differential miRNA expression in primary tumor and stroma of colorectal cancer patients 126
Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELOX-TARAV) in first line colorectal cancer: run in part 125
A phase II study of beweekly oxaliplatin plus infusional 5fluorouracil and folinic acid (FOLFOX4) as first-line treatment of advenced gastric cancer patients 125
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as initial treatment for metastatic colorectal cancer (TRIBE study): updated survival results and final molecular subgroups analyses. 125
MicroRNA profiling as predictive factor of complete pathological response to neoadjuvant chemoradiothetapy in patients with locally advanced cancer 124
Poly(adenosine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region. 123
C-erbB2 overexpression decreases the benefit of adiuvant tamoxifen in early breast cancer without axillary lymph node metastases. 122
Vinorelbine + mitomycin C as second-line treatment of metastatic breast cancer: a two-stage phase 2 study. 122
FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group. 122
A Metanalysis on the Interaction between HER2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer 121
Core curriculum. Oncologia clinica 121
Bevacizumab as 4th line treatment in metastatic colorectal cancer 120
Bevacizumab maintenance in metastatic colorectal cancer: How long? 120
A Post Hoc Analysis of Older Patients with Metastatic Colorectal Cancer Receiving Oxaliplatin-Based Chemotherapy Plus Bevacizumab: The Randomized Obelics Study 119
Surgery in lung cancer metastasis 118
Less frequently mutated genes in colorectal cancer: Evidences from next-generation sequencing of 653 routine cases 118
KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs, and beyond 117
Molecules and mechanisms to overcome oxidative stress inducing cardiovascular disease in cancer patients 116
Sphingosine Kinase 1 (SphK1) overespression contributes to cetuximab resistance in human colrectal cancer. 115
Multiple treatment lines and prognosis in metastatic colorectal cancer patients 115
KRAS mutation detection by high resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer 114
Bevacizumab-induced hypertension is a predictive marker of response and progression free survival in patients treated for metastatic colorectal cancer 114
A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients. 114
Identification of a novel truncating mutation in PALB2 gene by a multigene sequencing panel for mutational screening of breast cancer risk-associated and related genes 114
Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-lerm follow-up. 112
Prolactin receptor does not correlate with oestrogen and progesterone receptors in primary breast cancer and lacks prognostic significance. Ten year results of the Naples adjuvant (GUN) study. 112
Raltitrexed versus standard leucovorin-modulated 5Fluorouracil: results form the randomized phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). 112
Bevacizumab related arterial hypertension as a predictive marker in metastatic Colorectal Cancer (mCRC) patients 112
Correlation between bevacizumab-related hypertension and response in mCRC patients 112
Cardio-Oncology Challenges in Elderly Patients 110
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. 110
Forearm cutaneous metastasis of rectal adenocarcinoma: a case report 110
Dihydropyrimidine dehydrogenase polymorphisms in patients with gastrointestinal malignancies and their impact on fluoropyrimidine tolerability: Experience from a single Italian institution 109
HER2 as predictive marker of resistance to endocrine treatment for advanced bresat cancer: a metanalysis of published studies 109
A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme) 109
Prognostic significance of necrosis, elestosis, fibrosis and inflammatory cell reaction in operable breast cancer. 108
Cancro del colon-retto 107
Altri tumori gastrointestinali 107
Chemotherapy with mitomycin C and vinblastine in pretreated metastatic breast cancer. 106
FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic coloectal cancer (MCRC): results of the phase III tandomized TRIBE trial 100
Endocrine factors in the outcome of systemic adjuvant therapy of early breast cancer. 99
Mitomycin C and mitoxantrone in anthracycline-pretreated advanced breast cancer patients. A phase II study. 99
Two novel sequence variants in MSH2 gene in a patient who underwent cancer genetic counseling for a very early-onset epithelial ovarian cancer 99
Prognostic significance of multifocality in primary breast cancer. 98
Adjuvant chemoendocrine therapy for early breast cancer: is it worthwhile? 98
A predictive index of axillary nodal involvement in operable breast cancer. 98
Metastasis of colon cancer to the thyroid gland: a case diagnosed on fine-needle aspirate by a combined cytological, immunocytochemical and molecular approach. 97
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. 96
Unusual case of exacerbation of sub-acute descending necrotizing mediastinitis 95
Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer 95
Skin lesions: unusual presentation of gastric cancer 91
DNA-flow cytometry (ploidy and S-phase fraction) as prognostic factor in a retrospectine series of 515 primary breast cancer. 89
Predictive factors of complete response to neoadjuvant chemoradiotherapy in patients with rectal cancer 88
microRNA come parametri predittivi di risposta ai farmaci a bersaglio molecolare specifico nelle neoplasie del colon-retto 88
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial 87
KRAS Mutant Allele Specific Imbalance (MASI) assessment in routine samples of metastatic colorectal cancer patients 87
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. 86
Effect of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials 83
Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: a phase II study. 82
Totale 12.614
Salva come PNG Salva come JPEG
Categoria #
all - tutte 51.674
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 51.674
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022816 0 3 5 7 1 26 7 43 165 76 159 324
2022/2023999 144 59 26 50 94 85 6 89 152 238 40 16
2023/2024619 29 88 75 58 28 75 11 74 4 5 110 62
2024/20254.029 187 241 14 36 106 173 423 211 370 443 1.499 326
2025/20268.019 828 454 737 675 1.376 334 1.125 400 1.061 587 219 223
2026/2027246 184 62 0 0 0 0 0 0 0 0 0 0
Totale 16.062